Company profile: Ansun BioPharma
1.1 - Company Overview
Company description
- Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
Products and services
- DAS181: Host-directed recombinant sialidase protein that removes sialic acids from respiratory epithelial cell surfaces, blocking viral entry and treating parainfluenza and influenza infections
- Solid Tumor Therapies: Multi-modality platform-based assemblies targeting tumor and immune cells to prevent immune escape and restore surveillance using oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ansun BioPharma
Altesa BioSciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on accelerating the development of new treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altesa BioSciences company profile →
Aquapharm
HQ: United Kingdom
Website
- Description: Provider of drug discovery products based on the chemical diversity of marine micro-organisms, including novel pharmaceutical compounds and antibiotics for Gram negative and Gram positive infections, bio-manufactured nutraceuticals, personal care ingredients, and industrial biocatalysts. Maintains a proprietary library of over 7,000 marine micro-organisms and uses SeaRch™ technology to screen and induce production of biologically active compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquapharm company profile →
GNA Biosolutions
HQ: Germany
Website
- Description: Provider of molecular diagnostic technology using Pulse Controlled Amplification to combine ultrafast nucleic acid amplification with intrinsic sample preparation, enabling solutions for laboratory, on-site and point-of-care testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GNA Biosolutions company profile →
Inositec
HQ: Switzerland
Website
- Description: Provider of treatments for soft tissue calcification disorders based on its proprietary Inositune platform of inositol phosphate (IP6) analogs, with lead programs targeting vascular and renal calcification, including orphan indications; founded in 2015 as a spin-off of ETH Zurich.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inositec company profile →
T2 Biosystems
HQ: United States
Website
- Description: Provider of rapid, accurate infectious disease diagnostics, including the T2Dx Instrument, a fully automated system running tests directly from whole blood, the FDA-cleared T2Bacteria Panel for identifying sepsis-causing bacteria without blood culture, and T2Candida for detecting invasive candidiasis from whole blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T2 Biosystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ansun BioPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ansun BioPharma
2.2 - Growth funds investing in similar companies to Ansun BioPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ansun BioPharma
4.2 - Public trading comparable groups for Ansun BioPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →